These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18615172)

  • 1. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.
    Pae CU; Masand PS; Peindl K; Mannelli P; Han C; Marks DM; Patkar AA
    Prim Care Companion J Clin Psychiatry; 2008; 10(3):205-10. PubMed ID: 18615172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
    Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU
    Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.
    Pjrek E; Konstantinidis A; Assem-Hilger E; Praschak-Rieder N; Willeit M; Kasper S; Winkler D
    J Psychiatr Res; 2009 May; 43(8):792-7. PubMed ID: 19230909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study.
    Lundt L
    J Affect Disord; 2004 Aug; 81(2):173-8. PubMed ID: 15306145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram in seasonal affective disorder: results of an open trial.
    Pjrek E; Winkler D; Stastny J; Praschak-Rieder N; Willeit M; Kasper S
    Pharmacopsychiatry; 2007 Jan; 40(1):20-4. PubMed ID: 17327956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial.
    Shin C; Ko YH; Shim SH; Kim JS; Na KS; Hahn SW; Lee SH
    Psychiatry Investig; 2020 Aug; 17(8):796-803. PubMed ID: 32750760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.
    Rele S; Millet R; Kim S; Paik JW; Kim S; Masand PS; Patkar AA
    Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
    Gorman JM; Korotzer A; Su G
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder.
    Sinha S; Chary S; Thakur P; Talluri L; Reddy M; Verma KK; Saha P; Gupta VB; Ramaiah KA; Khanum SZ
    Cureus; 2021 Jul; 13(7):e16689. PubMed ID: 34513348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram continuation treatment prevents relapse of depressive episodes.
    Rapaport MH; Bose A; Zheng H
    J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD).
    Desan PH; Weinstein AJ; Michalak EE; Tam EM; Meesters Y; Ruiter MJ; Horn E; Telner J; Iskandar H; Boivin DB; Lam RW
    BMC Psychiatry; 2007 Aug; 7():38. PubMed ID: 17683643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
    Gommoll CP; Greenberg WM; Chen C
    J Drug Assess; 2014; 3(1):10-9. PubMed ID: 27536449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.